Research - Bettingen, Basel City, Switzerland
Amphilix AG is a biopharmaceutical company that discovers and develops small molecular chimera, a class of new therapeutic modalities with the potential to address some of the most challenging medical needs. Our portfolio includes preclinical candidates focusing on a novel mechanism for the treatment of diseases of the intestinal tract. The Amphilix AG proprietary chimera discovery engine enables the efficient design of drug-drug conjugates with defined structural features leading to superior Target Product Profiles. Amphilix AG is a Basel, Switzerland based company co-founded in 2020 by industry experts and Spirochem AG.
Gmail
Apache
Google Font API
Mobile Friendly
jPlayer